Abstract
Aim: Different studies have been performed to investigate stem cell administration as a promising tool for recovery of injured tissue in multiple sclerosis (MS), the most common demyelinating disease.
Methods: In the present systematic review, the electronic databases of PubMed and ScienceDirect were searched to screen English language studies published until April 2020.
Results: The results obtained from experimental autoimmune encephalomyelitis (EAE) animals revealed that modified mesenchymal stem cells (MSCs) transplantation was associated with remyelination, inflammation suppression and oligodendrocyte precursor cells regeneration. Clinical trials indicated that 70% of the patients with MS showed disease stabilization following MSCs administration.
Conclusion: Although MSC therapy has showed to be effective in the improvement of some patients with MS, designing larger placebo-controlled clinical trials with MSCs expressing immune- regulators or MSCs-exosomes may provide a novel viewpoint in the treatment of MS.
Keywords: Mesenchymal stem cells, multiple sclerosis, cellular therapy, remyelination, stabilization, transplantation.
Current Stem Cell Research & Therapy
Title:Preclinical Studies and Clinical Trials with Mesenchymal Stem Cell for Demyelinating Diseases: A Systematic Review
Volume: 16 Issue: 8
Author(s): Zahra Esmaeilizade, Bahar Mohammadi, Mir Davood Omrani, Sayyed Mohammad Hossein Ghaderian, Masoumeh Rajabibazl and Zahra Fazeli*
Affiliation:
- Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran,Iran
Keywords: Mesenchymal stem cells, multiple sclerosis, cellular therapy, remyelination, stabilization, transplantation.
Abstract:
Aim: Different studies have been performed to investigate stem cell administration as a promising tool for recovery of injured tissue in multiple sclerosis (MS), the most common demyelinating disease.
Methods: In the present systematic review, the electronic databases of PubMed and ScienceDirect were searched to screen English language studies published until April 2020.
Results: The results obtained from experimental autoimmune encephalomyelitis (EAE) animals revealed that modified mesenchymal stem cells (MSCs) transplantation was associated with remyelination, inflammation suppression and oligodendrocyte precursor cells regeneration. Clinical trials indicated that 70% of the patients with MS showed disease stabilization following MSCs administration.
Conclusion: Although MSC therapy has showed to be effective in the improvement of some patients with MS, designing larger placebo-controlled clinical trials with MSCs expressing immune- regulators or MSCs-exosomes may provide a novel viewpoint in the treatment of MS.
Export Options
About this article
Cite this article as:
Esmaeilizade Zahra, Mohammadi Bahar , Omrani Davood Mir , Ghaderian Mohammad Hossein Sayyed , Rajabibazl Masoumeh and Fazeli Zahra *, Preclinical Studies and Clinical Trials with Mesenchymal Stem Cell for Demyelinating Diseases: A Systematic Review, Current Stem Cell Research & Therapy 2021; 16 (8) . https://dx.doi.org/10.2174/1574888X16666210208162318
DOI https://dx.doi.org/10.2174/1574888X16666210208162318 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomedical Perspectives of Acute and Chronic Neurological and Neuropsychiatric
Sequelae of COVID-19
Current Neuropharmacology Fractalkine/CX3CR1 Signalling in Chronic Pain and Inflammation
Current Pharmaceutical Biotechnology Multiple Sclerosis, Gut Microbiota and Permeability: Role of Tryptophan Catabolites, Depression and the Driving Down of Local Melatonin
Current Pharmaceutical Design Potential Drugs Targeting Microglia: Current Knowledge and Future Prospects
CNS & Neurological Disorders - Drug Targets Mouse Models of Autoimmune Uveitis
Current Pharmaceutical Design From the Oxygen to the Organ Protection: Erythropoietin as Protagonist in Internal Medicine
Cardiovascular & Hematological Agents in Medicinal Chemistry Activation and Costimulation of Intestinal T Cells: Independent and Collaborative Involvement of CD43, OX40, and Ly-6C
Current Immunology Reviews (Discontinued) Advances in Design and Development of Inhibitors of Nitric Oxide Synthases
Current Enzyme Inhibition Modulation of Apoptosis: New Opportunities for Drug Discovery to Treat Autoimmune Thyroiditis
Recent Patents on Inflammation & Allergy Drug Discovery Alphavirus Vectors for Gene Therapy Applications
Current Gene Therapy TNF and TNF Receptors in TRAPS
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Sphingosine-1-Phosphate Receptors in the Central Nervous and Immune Systems
Current Drug Targets Probiotics as an Adjuvant Therapy in Major Depressive Disorder
Current Neuropharmacology Biology of Mesenchymal Stem Cells
Current Rheumatology Reviews Exploiting Microglial Functions for the Treatment of Glioblastoma
Current Cancer Drug Targets Demonstration of Biological and Immunological Equivalence of a Generic Glatiramer Acetate
CNS & Neurological Disorders - Drug Targets Inhibition of Type 1 Diabetes Development by Vitamin D Receptor Agonists
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents 2 Receptor Specific Ligand Conjugated Nanocarriers: An Effective Strategy for Targeted Therapy of Tuberculosis
Current Drug Delivery From Mice to Macaques – Animal Models of HIV Nervous System Disease
Current HIV Research The Role of D<sub>2</sub>-like Dopaminergic Receptor in Dopamine-mediated Modulation of Th17-cells in Multiple Sclerosis
Current Neuropharmacology